The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas
T. Cleverley, S. Peddineni, J. Guarner, F. Cingolani, H. Koehler, E. S. Mocarski, D. Kalman
This study shows imatinib accelerates immune responses to Mycobacterium marinum infection and reduces granuloma-associated pathology.
bioRxiv · Nov 28, 2022Immunology